FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922275854> ?p ?o ?g. }

• W2922275854 endingPage "870" @default.
• W2922275854 startingPage "862" @default.
• W2922275854 abstract "Pre-treatment factors that increase smokers’ risk of experiencing neuropsychiatric adverse events (NPSAEs) when quitting smoking are unknown. To identify baseline smoker characteristics beyond the history of mental illness that predict which participants were more likely to experience moderate to severe NPSAEs in EAGLES. A prospective correlational cohort study in the context of a multinational, multicenter, double-blind, randomized trial. Smokers without (N = 3984; NPC)/with (N = 4050; PC) histories of, or current clinically stable, psychiatric disorders including mood (N = 2882; 71%), anxiety (N = 782; 19%), and psychotic (N = 386; 10%) disorders. Bupropion, 150 mg twice daily, or varenicline, 1 mg twice daily, versus active control (nicotine patch, 21 mg/day with taper) and placebo for 12 weeks with 12-week non-treatment follow-up. Primary safety outcome was the incidence of a composite measure of moderate/severe NPSAEs. Associations among baseline demographic/clinical characteristics and the primary safety endpoint were analyzed post hoc via generalized linear regression. The incidence of moderate to severe NPSAEs was higher among smokers in the PC (238/4050; 5.9%) than in the NPC (84/3984; 2.1%). Three baseline characteristics predicted increased risk for experiencing clinically significant NPSAEs when quitting regardless of carrying a psychiatric diagnosis: current symptoms of anxiety (for every ~ 4-unit increase in HADS anxiety score, the absolute risk of occurrence of the NPSAE endpoint increased by 1% in both PC and NPC); prior history of suicidal ideation and/or behavior (PC, 4.4% increase; P = 0.001; NPC, 4.1% increase; P = 0.02), and being of White race (versus Black: PC, 2.9% ± 0.9 [SE] increase; P = 0.002; and NPC, 3.4% ± 0.8 [SE] increase; P = 0.001). Among smokers with psychiatric disorders, younger age, female sex, history of substance use disorders, and proxy measures of nicotine dependence or psychiatric illness severity also predicted greater risk. There were no significant interactions between these characteristics and treatment. Smokers with unstable psychiatric disorders or with current, active substance abuse were excluded from the study. Irrespective of cessation pharmacotherapy use, smokers attempting to quit were more likely to experience moderate to severe NPSAEs if they reported current anxiety or prior suicidal ideation at baseline and were White. In smokers with a psychiatric history, female sex, younger age, and greater severity of nicotine dependence were also predictive. ClinicalTrials.gov Identifier: NCT01456936" @default.
• W2922275854 created "2019-03-22" @default.
• W2922275854 creator A5002615180 @default.
• W2922275854 creator A5007719765 @default.
• W2922275854 creator A5009429601 @default.
• W2922275854 creator A5010255066 @default.
• W2922275854 creator A5018616843 @default.
• W2922275854 creator A5023634383 @default.
• W2922275854 creator A5048294207 @default.
• W2922275854 creator A5077623642 @default.
• W2922275854 creator A5083971769 @default.
• W2922275854 creator A5087610563 @default.
• W2922275854 date "2019-03-07" @default.
• W2922275854 modified "2023-09-30" @default.
• W2922275854 title "Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial" @default.
• W2922275854 cites W1845447069 @default.
• W2922275854 cites W1859891561 @default.
• W2922275854 cites W1955803833 @default.
• W2922275854 cites W1972830576 @default.
• W2922275854 cites W1988553489 @default.
• W2922275854 cites W1989268538 @default.
• W2922275854 cites W2056380667 @default.
• W2922275854 cites W2060663534 @default.
• W2922275854 cites W2062560594 @default.
• W2922275854 cites W2064042259 @default.
• W2922275854 cites W2094317192 @default.
• W2922275854 cites W2097295578 @default.
• W2922275854 cites W2124679681 @default.
• W2922275854 cites W2132276316 @default.
• W2922275854 cites W2134646088 @default.
• W2922275854 cites W2136253554 @default.
• W2922275854 cites W2141348739 @default.
• W2922275854 cites W2148083007 @default.
• W2922275854 cites W2166281097 @default.
• W2922275854 cites W2254462287 @default.
• W2922275854 cites W2339107149 @default.
• W2922275854 cites W2340896985 @default.
• W2922275854 cites W2521670955 @default.
• W2922275854 cites W2565020239 @default.
• W2922275854 cites W2742681578 @default.
• W2922275854 cites W2754044036 @default.
• W2922275854 cites W4210367804 @default.
• W2922275854 cites W4210565407 @default.
• W2922275854 cites W4241186196 @default.
• W2922275854 cites W4256484569 @default.
• W2922275854 cites W4292810003 @default.
• W2922275854 cites W4294253676 @default.
• W2922275854 doi "https://doi.org/10.1007/s11606-019-04858-2" @default.
• W2922275854 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6544691" @default.
• W2922275854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30847828" @default.
• W2922275854 hasPublicationYear "2019" @default.
• W2922275854 type Work @default.
• W2922275854 sameAs 2922275854 @default.
• W2922275854 citedByCount "15" @default.
• W2922275854 countsByYear W29222758542019 @default.
• W2922275854 countsByYear W29222758542020 @default.
• W2922275854 countsByYear W29222758542021 @default.
• W2922275854 countsByYear W29222758542022 @default.
• W2922275854 countsByYear W29222758542023 @default.
• W2922275854 crossrefType "journal-article" @default.
• W2922275854 hasAuthorship W2922275854A5002615180 @default.
• W2922275854 hasAuthorship W2922275854A5007719765 @default.
• W2922275854 hasAuthorship W2922275854A5009429601 @default.
• W2922275854 hasAuthorship W2922275854A5010255066 @default.
• W2922275854 hasAuthorship W2922275854A5018616843 @default.
• W2922275854 hasAuthorship W2922275854A5023634383 @default.
• W2922275854 hasAuthorship W2922275854A5048294207 @default.
• W2922275854 hasAuthorship W2922275854A5077623642 @default.
• W2922275854 hasAuthorship W2922275854A5083971769 @default.
• W2922275854 hasAuthorship W2922275854A5087610563 @default.
• W2922275854 hasBestOaLocation W29222758541 @default.
• W2922275854 hasConcept C118552586 @default.
• W2922275854 hasConcept C120665830 @default.
• W2922275854 hasConcept C121332964 @default.
• W2922275854 hasConcept C126322002 @default.
• W2922275854 hasConcept C139719470 @default.
• W2922275854 hasConcept C142724271 @default.
• W2922275854 hasConcept C151730666 @default.
• W2922275854 hasConcept C162324750 @default.
• W2922275854 hasConcept C168563851 @default.
• W2922275854 hasConcept C197934379 @default.
• W2922275854 hasConcept C2776867660 @default.
• W2922275854 hasConcept C2777053506 @default.
• W2922275854 hasConcept C2777843972 @default.
• W2922275854 hasConcept C2779343474 @default.
• W2922275854 hasConcept C2779547902 @default.
• W2922275854 hasConcept C558461103 @default.
• W2922275854 hasConcept C61511704 @default.
• W2922275854 hasConcept C71924100 @default.
• W2922275854 hasConcept C86803240 @default.
• W2922275854 hasConceptScore W2922275854C118552586 @default.
• W2922275854 hasConceptScore W2922275854C120665830 @default.
• W2922275854 hasConceptScore W2922275854C121332964 @default.
• W2922275854 hasConceptScore W2922275854C126322002 @default.
• W2922275854 hasConceptScore W2922275854C139719470 @default.
• W2922275854 hasConceptScore W2922275854C142724271 @default.
• W2922275854 hasConceptScore W2922275854C151730666 @default.
• W2922275854 hasConceptScore W2922275854C162324750 @default.

• next